Semaglutide
Författaruppgift saknas
Tidskrift saknas · review PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för semaglutide. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
43 träffarThe Ethics of Ozempic and Wegovy.
Ryan N, Savulescu J.
J Med Ethics · research-article; journal article · DOI 10.1136/jme-2024-110374Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP, SURMOUNT-5 Trial Investigators.
N Engl J Med · clinical trial, phase iii; comparative study; equivalence trial; multicenter study; journal article · DOI 10.1056/nejmoa2416394A renal indication for semaglutide (Ozempic).
Författaruppgift saknas
Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2025.1723dThe prevalence and consequences of support for off-label Ozempic prescriptions.
Callaghan T, Motta M, Stein M, Goidel K.
Health Econ Policy Law · journal article · DOI 10.1017/s1744133124000306Semaglutide, Popularly Known as Ozempic-What the Facial Plastic Surgeon Needs to Know.
Sciscent BY, Goldrich D, Eberly HW, Walen S.
Facial Plast Surg Aesthet Med · journal article · DOI 10.1089/fpsam.2024.0083Ozempic and dental therapy.
Kosinski TF.
Gen Dent · editorialSemaglutide (Ozempic<sup>®</sup>) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss.
Mailhac A, Pedersen L, Pottegård A, Søndergaard J, Mogensen T, Sørensen HT, Thomsen RW.
Clin Epidemiol · research-article; journal article · DOI 10.2147/clep.s456170Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI, Vonica RC, Faur AM, Streinu DR, Muntean C.
Int J Mol Sci · systematic review; review-article; journal article · DOI 10.3390/ijms25084346GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide).
Manoharan SVRR, Madan R.
Innov Clin Neurosci · journal article; case reportsImplications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
Humphrey CD, Lawrence AC.
Facial Plast Surg · journal article · DOI 10.1055/a-2148-6321Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
Snitker S, Andersen A, Berg B, van Marle S, Sparre T.
Diabetes Obes Metab · brief-report; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.14349Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists.
Kane MP, Triplitt CL, Solis-Herrera CD.
Am J Health Syst Pharm · review-article; journal article · DOI 10.1093/ajhp/zxaa413Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study.
Hepprich M, Zillig D, Florian-Reynoso MA, Donath MY, Rudofsky G.
Diabetes Ther · research-article; journal article · DOI 10.1007/s13300-021-01016-yOnce-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group.
N Engl J Med · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa2032183Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study.
Williams DM, Ruslan AM, Khan R, Vijayasingam D, Iqbal F, Shaikh A, Lim J, Chudleigh R, Peter R, Udiawar M, Bain SC, Stephens JW, Min T.
Diabetes Ther · research-article; journal article · DOI 10.1007/s13300-021-01015-zCombination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals.
Yang X, Wu S, Feng Z, Yi G, Zheng Y, Xia Z.
Life Sci · journal article · DOI 10.1016/j.lfs.2020.119013Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Ji L, Dong X, Li Y, Li Y, Lim S, Liu M, Ning Z, Rasmussen S, Skjøth TV, Yuan G, Eliaschewitz FG.
Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1111/dom.14232Semaglutide is safe and efficacious for NASH resolution.
Dickson I.
Nat Rev Gastroenterol Hepatol · comment; journal article · DOI 10.1038/s41575-020-00396-zOptimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach.
Isaacs DM, Kruger DF, Spollett GR.
Diabetes Spectr · research-article; journal article · DOI 10.2337/ds20-0016Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide.
Hearn EB, Sherman JJ.
Diabetes Spectr · research-article; journal article · DOI 10.2337/ds20-0033Oral GLP1 Analog: Where Does the Tide Go?
Gardner H, Hamdy O.
Clin Med Insights Endocrinol Diabetes · review-article; review; journal article · DOI 10.1177/1179551420984130The evidence for oral semaglutide in type 2 diabetes from a managed care perspective.
Heile M, Taddei-Allen P.
Am J Manag Care · research support, non-u.s. gov't; journal article · DOI 10.37765/ajmc.2020.88553Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care.
Lingvay I, Taddei-Allen P, Dougherty T.
Am J Manag Care · research support, non-u.s. gov't; journal article · DOI 10.37765/ajmc.2020.88555A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA, NN9931-4296 Investigators.
N Engl J Med · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa2028395Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.
Shi A, Xie P, Nielsen LL, Skjøth TV, He X, Haugaard SP.
Adv Ther · research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s12325-020-01548-yOral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
Semenya AM, Wilson SA.
Am Fam Physician · journal articlePharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus.
Clements JN, Isaacs D, Hartman RE, Gambill K.
Clin Pharmacokinet · review; journal article · DOI 10.1007/s40262-020-00951-6Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis.
Chang YF, Zhang D, Hu WM, Liu DX, Li L.
J Clin Neurosci · journal article · DOI 10.1016/j.jocn.2020.09.054Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
Blakely KK, Weaver K.
Nurs Womens Health · journal article · DOI 10.1016/j.nwh.2020.07.005